Bruynzeel P L, Meurs H, Leferink J G, van den Berg W
Bull Eur Physiopathol Respir. 1985 Sep-Oct;21(5):45s-52s.
Continued exposure of target cells to a hormonal agonist frequently leads to a blunted response to that agonist. This process has been termed desensitization, refractoriness, tolerance or tachyphylaxis. The receptor involved in case of beta-sympathomimetics is the beta-adrenergic receptor. When the clinical aspects of beta-adrenergic receptor desensitization are considered, a number of points need serious attention: 1) the route of administration of the drug and the concentration of the drug reached at the receptor site; 2) other factors which may cause reduced responsiveness of the beta-adrenergic receptor besides beta-sympathomimetics and interfere with this process; 3) the different cell-types which are studied and thought to be representative for processes taking place at lung tissue level; 4) the in vivo parameter(s) chosen to describe desensitization; 5) the difference between normal and asthmatic subjects; 6) the mechanism behind desensitization. The paper concerns a review of these points. Since the clinical findings with respect to the induction of desensitization by beta-sympathomimetics are rather controversial, the therapeutic advice should be: use it with caution.
靶细胞持续暴露于激素激动剂常常会导致对该激动剂的反应减弱。这个过程被称为脱敏、不应性、耐受性或快速耐受性。β-拟交感神经药情况下所涉及的受体是β-肾上腺素能受体。当考虑β-肾上腺素能受体脱敏的临床方面时,有几点需要认真关注:1)药物的给药途径以及在受体部位达到的药物浓度;2)除β-拟交感神经药之外可能导致β-肾上腺素能受体反应性降低并干扰此过程的其他因素;3)所研究的且被认为代表肺组织水平发生过程的不同细胞类型;4)选择用来描述脱敏的体内参数;5)正常人和哮喘患者之间的差异;6)脱敏背后的机制。本文对这些要点进行综述。由于关于β-拟交感神经药诱导脱敏的临床发现颇具争议,治疗建议应为:谨慎使用。